Clinical evaluation of intravenous hexoprenaline in bronchial asthma.
5 ug of hexoprenaline given intravenously resulted in a significant relief of airway obstruction in 12 out of 16 patients with acute attack of bronchial asthma. It produced a 40% increase in peak expiratory flow rate (PEFR) with a peak at 5 minutes and a 12% increase was still present at 2 hours. It produced only minimal cardiovascular side effects. As a bronchodilator, it was as effective as 0.5 mg of addrenaline given subcutaneously though the latter suffered from considerable cardiovascular side effects as shown by a 12% elevation of systolic blood pressure and a 16% reduction in the diastolic blood pressure.
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001794:Blood Pressure; D002648:Child; D002986:Clinical Trials as Topic; D004837:Epinephrine / Q000008:administration & dosage; D005260:Female; D006594:Hexoprenaline / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007263:Infusions, Parenteral; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D010627:Phenethylamines / Q000008:administration & dosage*; D011674:Pulse
D010627:Phenethylamines; D006594:Hexoprenaline; D004837:Epinephrine